Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q4 FY26 Earnings Presentation
22 slides from Caplin Point Laboratories's earnings presentation, May 2026
Slide 1: Earnings Presentation Q4 FY26
EARNINGS PRESENTATION Q4 FY26 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* May 2026 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Evolution Over the Decades
Evolution Over the Decades Rs. 600 Cr. Expansion, Incorporates Caplin CSU Work on Regulated CRO wing Amaris Steriles USA Inc for commencement of Listed on Stock Started outsourcing from Markets Injectable unit Started first commercial Clinical gets USFDA launching own label in operations Exchange Ch
Slide 3: Q4 FY26 Income Statement
Q4 FY26 Income Statement Revenue from Operations Gross Profit EBITDA 19.4% 17.9% 20.0% YoY YoY YoY 223 233 600 355 328 194 543 502 301 Q4 FY25 Q3 FY26 Q4 FY26 Q4 FY25 Q3 FY26 Q4 FY26 Q4 FY25 Q3 FY26 Q4 FY26 EBIT PAT Earnings Per Share 21.0% 19.0% YoY YoY 204 214 173 22.38 166 21.56 177 18.75 145 Q4
Slide 4: Q4 FY26 Profit Margins
Q4 FY26 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 60.4% 38.7% 60.0% 37.0% 59.2% 36.7% Q4 FY25 Q3 FY26 Q4 FY26 Q4 FY25 Q3 FY26 Q4 FY26 EBIT Margins (%) PAT Margins (%) 35.4% 28.8% 34.0% 27.5% 33.5% 27.5% Q4 FY25 Q3 FY26 Q4 FY26 Q4 FY25 Q3 FY26 Q4 FY26 4
Slide 5: FY26 Income Statement
FY26 Income Statement Revenue from Operations Gross Profit EBITDA 12.9% 13.3% 17.9% YoY YoY YoY 2,187 1,322 1,167 876 1,937 743 FY25 FY26 FY25 FY26 FY25 FY26 EBIT PAT Profit Margins 18.6% 20.1% YoY YoY 60.2% 60.4% 804 650 541 677 38.1% 36.5% 33.3% 34.9% 26.6% 28.2% FY25 FY26 FY25 FY26 FY25 FY26 Gros
Slide 6: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said: Dr. Sridhar Ganesan “The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delive
Slide 7: Q4 FY26 Highlights (Emerging Markets)
Q4 FY26 Highlights (Emerging Markets) 01 02 03 03 04 05 Mexico Update – Company has Caplin’s “China 2.0” strategy of Chile Update – Company continues partnering with Companies that have received approvals for 25 products robust progress with tender and Company enters Brand Marketing in CNS segment i
Slide 8: Q4 FY26 Highlights (US and Regulated markets)
Q4 FY26 Highlights (US and Regulated markets) 01 02 03 03 04 05 CSL has filed 54 products (of Caplin has received 10 ANDA which 32 are approved) in Company’s development Caplin Steriles Limited (CSL) approvals in FY26, and has also multiple Non-US markets, such pipeline remains strong, with continue
Slide 9: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved). R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue Continuous capex investment of over Rs. 870 Cr over last 5 years towards 2 enhanced manufacturing and R&D capabilities, from internal accruals.
Slide 10: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY26 Operating Revenue (Emerging Markets) (Emerging Markets) 35% 21% 3% 75% 25% 20% 76% 45% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 11: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 11
Slide 12: Caplin Point Structure
Caplin Point Structure Caplin Point Laboratories Caplin Point Far East Ltd Caplin Steriles Ltd (BSE: 524742| NSE: CAPLIPOINT) (India) Subsidiaries Manufacturing Units: Manufacturing Units: • CP I: Puducherry • Nuevos Eticos Neo Ethicals S.A. • CP IV: Gummidipoondi • CP X: Vishakhapatnam Guatemala •
Slide 13: Manufacturing and R&D Platform
Manufacturing and R&D Platform Location of Plants and Facilities Tamil Nadu, India 1. SIDCO, Kakkalur, Near Chennai 1 2 2. Gummidipoondi, Chennai (CP4) 43 3. Thervoy SIPCOT, Chennai 5 4. Corporate Office, Chennai 5. Suthukeny, Puducherry (CP1) 6. APIIC, Visakhapatnam CP I CP III Puducherry Chengalpa
Slide 14: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline Lyophilized CP1, Suthukeny, Caplin Plant I Injectables and Dual Existing Markets Completed Completed Puducherry Chamber Syringes API Facility Visakhapatnam, Existing and Regulated General API Completed Comp
Slide 15: Caplin Point's Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 16: Experienced and Visionary Board of Directors (1/2)
Experienced and Visionary Board of Directors (1/2) Mr. C.C. Paarthipan Dr. Sridhar Ganesan Mr. Ashok Partheeban Mr. Vivek Partheeban Dr. KC John Chairman Managing Director Vice Chairman Vice Chairman Independent Director 30+ Years of 35+ Years experience 23+ Years experience in 20+ years of experien
Slide 17: Experienced and Visionary Board of Directors (2/2)
Experienced and Visionary Board of Directors (2/2) Dr. R Nagendran Mr S Deenadayalan Mr. R. Vijayaraghavan Mrs. Susan Mathew Independent Director Independent Director Independent Director Independent Director Ph.D in Ecology and Post Graduate degree 35+ years of experience Post Graduate degree Ethol
Slide 18: Q4 FY26 Consolidated Income Statement
Q4 FY26 Consolidated Income Statement In Rs. Crores Particulars Q4 FY26 Q4 FY25 YoY (%) Q3 FY26 QoQ (%) FY26 FY25 YoY (%) Revenue from Operation 600.16 502.45 19.4% 542.77 10.6% 2,187.19 1,937.47 12.9% Other Income 28.36 25.74 10.2% 33.68 (15.8%) 115.54 96.43 Total Revenue 628.52 528.19 19.0% 576.45
Slide 19: Visit Our Real Time ESG Disclosure Platform
Visit Our Real Time ESG Disclosure Platform At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations. Map our ESG framework with 35+ different frameworks Download ESG data Access to ESG factsheet Click to access ESG Profil
Slide 20: ESG and CSR
ESG and CSR ESG Commitments CSR INR 8.49 Crores Community Development Amount spent on CSR in FY25 ✓ Caplin Group’s state-of-the-art hospital and diagnostic centre at Gummidipoondi, Chennai INR 4.16 Crores Amount spent on CSR in FY26 Recycled Waste ✓ 60.2 MT waste recycled in 2025 Environmental &Soci
Slide 21: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 22: Investor Contact
Mr G Venkatram [email protected] Simran Malhotra / Soham Arora +91 99454 72589 [email protected] 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited – All Rights Reserved. “Caplin Po
Caplin Point Laboratories — Q4 FY26 Earnings Presentation on 6ix